Get the Stockscreener App
4.59
4.16%
-0.22
Adverum Biotechnologies Inc stock is traded at $4.59, with a volume of 72,489.
It is down -4.16% in the last 24 hours and up +52.65% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$4.81
Open:
$4.86
24h Volume:
72,489
Relative Volume:
0.24
Market Cap:
$96.53M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.7637
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
-13.02%
1M Performance:
+52.65%
6M Performance:
+34.40%
1Y Performance:
-39.74%
1-Day Range:
$4.58
$4.945
1-Week Range:
$4.58
$5.59
52-Week Range:
$1.78
$8.56
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.60 | 100.93M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.74 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.34 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Real time social sentiment graph for Adverum Biotechnologies Inc.GDP Growth & Reliable Intraday Trade Plans - newser.com
What’s the recovery path for long term holders of Adverum Biotechnologies Inc.2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Is Adverum Biotechnologies Inc. stock attractive for growth ETFs2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
Analyzing recovery setups for Adverum Biotechnologies Inc. investorsIPO Watch & High Return Stock Watch Alerts - newser.com
Can Adverum Biotechnologies Inc. (AVU0) stock sustain revenue momentumGap Up & Smart Allocation Stock Tips - newser.com
Price action breakdown for Adverum Biotechnologies Inc.2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Can Adverum Biotechnologies Inc. recover in the next quarterAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Adverum Biotechnologies Inc.’s volatility index tracking explainedFed Meeting & High Conviction Trade Alerts - newser.com
Adverum Biotechnologies (NASDAQ:ADVM) Stock Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Visual trend scoring systems applied to Adverum Biotechnologies Inc.Market Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Short interest data insights for Adverum Biotechnologies Inc.Earnings Overview Summary & Safe Entry Trade Signal Reports - newser.com
Adverum Biotechnologies' (ADVM) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Is Adverum Biotechnologies Inc. (AVU0) stock a buy during volatile marketsGlobal Markets & Technical Buy Zone Confirmations - newser.com
Will Adverum Biotechnologies Inc. stock gain from lower inflationWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
Does Adverum Biotechnologies Inc. (AVU0) stock trade below intrinsic valueJuly 2025 Trade Ideas & Fast Gaining Stock Reports - newser.com
Using data filters to optimize entry into Adverum Biotechnologies Inc.July 2025 Summary & Verified Technical Signals - newser.com
Adverum Biotechnologies Inc Stock Analysis and ForecastShort Interest Overview & Explosive Profit Potential - earlytimes.in
What technical models suggest about Adverum Biotechnologies Inc.’s comebackWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
What MACD trends signal for Adverum Biotechnologies Inc. (AVU0) stockJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Will Adverum Biotechnologies Inc. stock return to pre crisis levelsJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
Should you wait for a breakout in Adverum Biotechnologies Inc.July 2025 Technicals & Real-Time Stock Movement Alerts - newser.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Will Adverum Biotechnologies Inc. stock go up soon2025 AllTime Highs & Safe Capital Growth Tips - newser.com
After losing 28% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain - simplywall.st
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year - Yahoo Finance
What drives Adverum Biotechnologies Inc stock priceInstitutional Holding Changes & Smarter Trades Backed by Machine Learning - earlytimes.in
Applying chart zones and confluence areas to Adverum Biotechnologies Inc.Volume Spike & Daily Growth Stock Tips - newser.com
Adverum Biotechnologies (NASDAQ:ADVM) Shares Cross Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):